Enhancing Chronic Obstructive Pulmonary Disease Management through Optimized Peak Inspiratory Flow Rate and Inhaler Strategies: Literature Review | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Articles in Press, Accepted Manuscript, Available Online from 31 December 2024 | ||
| Document Type: Review Article | ||
| DOI: 10.21608/bfsa.2024.306558.2209 | ||
| Authors | ||
| Mohamed Ismail Hassan* 1; Nabila Ibrahim Laz2; Yasmin M. Madney3; Hadeer S. Harb4; Mohamed E. A. Abdelrahim5 | ||
| 1Department of Pharmacy Practice, Faculty of Pharmacy, Sinai University-Al Arish Campus, North Sinai, Egypt, 45511 | ||
| 2Chest Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. | ||
| 3Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-suef, Egypt | ||
| 4Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt | ||
| 5Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. | ||
| Abstract | ||
| Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and progressive respiratory condition that significantly impacts the quality of life of affected individuals. The management of COPD, particularly through bronchodilator inhalers, is critical for controlling symptoms and improving lung function. This literature review aims to explore various facets of COPD management, with a focus on Peak Inspiratory Flow Rate (PIFR) and the efficacy of Dry Powder Inhalers (DPIs). The key points derived from the review are as follows: The review was designed to address three primary questions related to COPD management: the relationship between suboptimal PIFR and lung function, the modifiability of PIFR, and the impact of a preliminary dose of pressurized Metered Dose Inhalers (pMDI) on the efficacy of DPIs and lung function. Suboptimal PIFR in COPD patients can adversely affect the progression of the disease and the outcomes of treatment. Addressing suboptimal PIFR through personalized inhaler selection and patient education is crucial for improving disease management and treatment effectiveness. Administering a preliminary dose of pMDI can enhance the effectiveness of DPIs in COPD patients with suboptimal PIFR. Conclusion and Future Directions: The review concludes that further research is needed to explore the potential benefits of addressing suboptimal PIFR and the role of preliminary pMDI doses in improving DPI efficacy. This literature review underscores the importance of comprehensive assessments and tailored treatment approaches in managing COPD, particularly for patients with suboptimal PIFR. It highlights the need for ongoing research to optimize inhaler therapy and improve patient outcomes. | ||
| Keywords | ||
| Chronic Obstructive Pulmonary Disease; Peak Inspiratory Flow Rate; Dry Powder Inhaler; Preliminary Dose | ||
|
Statistics Article View: 135 |
||
